#ObesityMedicine #MetabolicHealth #GLP1 #ClinicalTrials #HealthcareInnovation #Semaglutide #Orforglipron #CagriSema #Retatrutide #Wegovy To view or add a comment, sign in : Eli Lilly and Company just released Phase 3 ATTAIN-MAINTAIN data on orforglipron, a once daily oral GLP-1 receptor agonist, and I think it speaks directly to one of the most painful realities my patients face: not losing weight, but it - Participants first completed 72 weeks on high-dose injectable semaglutide (Wegovy) or tirzepatide (Zepbound) in SURMOUNT-5, with very large average weight reductions
This was only one study, and it only involved 127 participants, so it should not be taken as the final word on the matter
Well take the time to understand your unique needs and ensure you're set up for success
Elevate your beauty routine with this advanced liquid collagen drink if youre ready to firm, smooth, and refresh the look of your skin from the inside out
Smaller, more frequent meals are often easier to tolerate than large portions
